117 results about "SARS coronavirus IgG" patented technology

Monoclonal antibody reagents that recognize the SARS-coronavirus (SARS-HCoV) are needed urgently. In this report we describe the development and immunochemical characterisation of mAbs against the SARS-HCoV based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of seventeen mAbs. Five mAbs exhibited Western immunoblot reactivity with the denatured spike protein, of which two demonstrated the ability to neutralize SARS-HCoV in vitro. Another four Western immunoblot-negative mAbs also neutralize the virus. These antibodies will be useful for the development of diagnostic tests, pathogenicity and vaccine studies.

Methods for determining the presence of SARS-CoV in a test sample that include targeting the SARS-CoV 5′ leader sequence or the SARS-CoV 3′ terminal sequence.

The invention provides a group of polyhydroxy stilbene compounds, their preparing process and use for suppressing and eradicating SARS coronavirus. The preparing process comprises, preparing phosphonic ester by reacting multi-alkyl substituted chloro (bromo) methoxyl or pyridine compounds with triethyl phosphate, then reacting phosphonate ester compound with multi-alkyl (oxy) phenylpyridine methyl aldehyde to obtain multi-alkyl (oxy) stilbene compounds. Finally acting with boron tribromide to obtain polyhydroxy stilbene compounds with substituent groups.

An immunoadjuvant used to prepare the antiviral vaccine or medicine for increasing the immune activity of the antigens for HBV, HCV, SARS coronavirus, fowl influenza virus, etc is a kind of human or animal's novel heat shock proteins gp96, hsp108 and hsp70.

An antibody against the nucleocapsidprotein of SARS coronavirus, the method for using said antibody to detect the SARS coronavirus or its antigen, and the reagent kit and relative products for said method are disclosed.

The present invention relates to isolation and characterization of a class of isolated novel viruses which is the precursor of the virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The precursor virus which is a SARS coronavirus-like virus (“SCoV-like virus”) is identified to be morphologically and phylogenetically similar to hSARS virus. The present invention relates to a nucleotide sequence comprising the genomic sequence of the SCoV-like virus. The invention further relates to nucleotide sequences comprising a portion of the genomic sequence of the SCoV-like virus. The invention also relates to the deduced amino acid sequences of the SCoV-like virus. The invention further relates to the nucleic acids and peptides encoded by and / or derived from these sequences and their use in diagnostic methods and therapeutic methods. The invention further encompasses chimeric or recombinant viruses encoded by said nucleotide sequences and antibodies directed against polypeptides encoded by the nucleotide sequences. Furthermore, the invention relates to vaccine preparations comprising the SCoV-like virus, including recombinant and chimeric forms of said virus.

This invention relates generally to human monoclonal antibodies against SARS-CoV, epitopes bound by the bodies as well as to methods for use thereof.

A yolk antibody for SARS coronavirus is prepared through injecting the antigen, which may be recombinant genetic protein S, M, or E,or the antigen epitope for said protein able to represent SARS coronavirus, or the synthetic polypeptide of said protein, etc, in health hen for primary immunizing, booster immunizing, collecting its egg, extracting yolk, and extracting the yolk antibody from it. It can also be prepared to become liquid preparation. It can be used to prevent SARS.

The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.

The invention provides a method for blocking SARS coronavirus to infect cell with polypeptide or its derivative. The cistine series of polypeptide comes from two heptad repeat districts HR1 and HR2 of SARS coronavirus spike(S) protein. The invention also provides a method for producing the functional similarity with HR1 and HR2. the invention provides a method for producing HR polypeptide and its derivant with coalescence expression method. All the peptides have rejection capability to SARS.

The invention discloses an optimized SARS coronary virus spike protein gene, which codes the SARS coronary virus S protein or immunogenicity fragment, and has 77+ / -3% homology with SARS coronary virus S protein coding sequence(such as SEQ ID NO: 1). The invention also provides vector, host cell and vaccine composition containing a optimized S protein coding sequence, whose expression efficiency is higher in mammal cell, So can stimulate the immune response in mammal to SARS.

Fusion proteins of recombinant SARS coronavirus structural proteins, their production and uses are provided. An optimized SARS coronavirus S protein gene which can be highly expressed in the mammalian cell strains and SARS coronavirus S protein variants comprising deletion, modification or mutation amino acids 318-510 corresponding to SARS coronavirus S protein are also provided.

The present invention relates to methods of detecting the presence or absence of antibody to SARS coronavirus in a sample, based on the discovery that the S, M, E, N and U274 proteins of SARS coronavirus are antigenic. Such methods may be used to diagnose whether a patient has been infected by or exposed to SARS coronavirus. Antibodies directed against S, M, E, N and U274 proteins of SARS are also provided.

The invention discloses a method for detecting pathogens of infectious diseases, which possibly exist in a biological sample. The pathogens of the infectious diseases comprise avian influenza virus H5 subtype, avian influenza virus H7 subtype, SARS coronavirus, hanta virus, plague yersinia pestis and bacillus anthracis. The method comprises amplifying a nucleic acid fragment of a biological sample and detection by a probe. The invention also provides a primer for amplification and a probe for detection. The invention also provides a kit including the primer. The method has the advantages of high flexibility, strong specificity, easy operation, wide sample range, the detection for the pathogens of various infectious diseases at the same time and the suitability for early diagnosis of respiratory infectious diseases.

The present invention relates to oligonucleotides useful for determining the presence of SARS coronavirus in a test sample. The oligonucleotides of the present invention may be incorporated into detection probes, capture probes and amplification oligonucleotides, or used in various combinations thereof.

This invention relates to a detection mode of SARS virus antibody and a preparing method of the box for rapid diagnosis reagent. The checking method includes that (1) putting antihuman Ig antibody marked by colloidal gold in the carrier, and coating detecting thread made of variant antigen of SARS coronavirus and controlling thread made of antipest IgG antibody in the detecting carrier connecting with the marked one. (2) putting human serum in the marked carrier. The box for rapid diagnosis reagent includes checkerboard marked by variant antibody of SARS coronavirus, which comprises water-absorbing layer of adding-kind edge, detecting layer and water-absorbing layer of water-uptake edge. There is antihuman Ig antibody layer between detecting layer and water-absorbing layer of water-uptake edge, and in the detecting layer there is detecting thread made of variant antigen of SARS coronavirus and controlling thread made of antipest IgG antibody coating.

The present invention relates to the use of a matured, glycosylated Spike (S) protein of SARS Coronavirus, fragments of the S protein, methods for producing the same, their use in detecting SARS infection, and their use or the use of their corresponding antibodies to treat patients suffering from SARS.

The present invention relates to an assay system and methods for detecting SARS coronavirus (SARS-CV) from the samples (especially for urine) of suspected patient in the control of SARS to provide updated information of prognosis as well as the criteria for discharging a recovered patient from a hospital. The present invention also relates to an apparatus for performing the integration of thermal and magnetic control in the same apparatus to largely reduce the time of hybridization less than 20 minutes and the whole process of SARS-CV detection is less than 5 hours.

The present invention relates to one kind of reagent for colloidal gold chromatographic analysis of SARS coronavirus antigen. The reagent consists of coating film, absorbent paper, and glass fiber film coated with gold mark antibody adhered successively together. The present invention is used in colloidal gold chromatographic analysis of SARS coronavirus antigen in hospital, airport, custom, household, etc. Using it can obtain detection result in several minutes and this is favorable to prevent diffusion of epidemic situation.

Disclosed herein are peptide compounds and the application thereof to the detection and inhibition of SARS coronavirus. Composed of dipeptides, the compounds for detecting and inhibiting SARS coronavirus can be readily synthesized and produced at low cost. In addition, they can be stored safely for a long period of time. The dipeptide compounds are useful as inhibitors of SARS coronavirus as well as acting as excellent capturing materials of SARS coronavirus.

The present invention relates to a new strain of coronavirus and its application. Said invention utilizes the throat-swabbed cell colture of SARS patient to separate out a new type coronavirus, called by name of SARS coronavirus Fudan I strain. By infecting Vero E 6 cell and patient's serum the indirect FA display is positive, after the influenza virus A and B, RS virus and pathogens of pneumococcus, etc. are excluded, the tests show that said separated coronavirus is a variant strain of new coronavirus. Said strain can be used for providing basis for preparing SARS diagnosis reagent and researchnig and producing medicine for resisting and curing SARS disease.

The present invention relates reagent kit for IgG immunoblotting diagnosis of SARS coronavirus antibody. The reagent kit consists of solid film, antiantibody of enzyme label and corresponding chromogenic substrate. The solid film is obtained through purifying SARS coronary totivirus lysate liquid antibody or recombining mixed antigen, gel electrophoresis to separate and transferring to film. The antiantibody of enzyme label is compounded with rabbet's antihuman IgG labeled with horseradish peroxidase or sheep's antihuman IgG labeled with alkaline phosphatase, 0.01 % concentration thimerosal as protecting agent, ox serum protein in 1 wt% and PBS in pH 7.4 in 0.01 M. The present invention may be used in detecting several kinds of antigen and antibody in clinical test department and sanitary epidemic prevention department.

The present invention is serial small molecular inhibitor designed based on the crystal structure of main proteinase of SARS coronavirus and in the structural general expression as shown. The present invention also provides the preparation process of the small molecular inhibitor and its use in preparing medicine for preventing and treating various kinds of coronavirus infection.

Animal models for severe acute respiratory syndrome-coronavirus infection of humans are needed to elucidate SARS pathogenesis and develop vaccines and antivirals. Transgenic mice were developed expressing human angiotensin-converting enzyme 2, a functional receptor for the virus, under the regulation of a global promoter. A transgenic lineage, designated AC70, was among the best characterized against SARS coronavirus infection, showing weight loss and other clinical manifestations before reaching 100% mortality within 8 days after intranasal infection. Inflammatory mediators were also detected in these tissues, coinciding with high levels of virus replication. In contrast, infected transgene-negative mice survived without showing any clinical illness. The severity of the disease developed in these transgenic mice, AC70 in particular, makes these mouse models valuable not only for evaluating the efficacy of antivirals and vaccines, but also for studying SARS coronavirus pathogenesis and infection by other coronaviruses utilizing human ACE2 for viral entry into cells.

A SARS-Cov gene vaccine based on epitope is configured from the carrier which is a plasmid able to be used for human body and the target antigen which is several B cell epitopes in the extrinsic B protein antigen of human SARS coronavirus through codon optimizing and genetic engineering. Its preparing process is also disclosed.

The invention relates to a kind of polypeptide for SARS coronavirus and its application. The amnio acid squence is SEQ ID NO: 1 or its derivant squence. The sifted antigen epitope LH21 is N section of protein coded by ORF3a gene, its immunity is strong, and the clinical diagnosis value is good. The antibody prepared with said epitope can be used to check virus antigen.

The present invention discloses a gene vaccine for resisting SARS coronavirus and its application, including eucaryotic expressino plasmid containing total or partial gene fragment of total-length gene sequence of SARS coronavirus S protein. The nucleotide sequence of coded SARS coronavirus S protein can be operatively connected with a promotor, then it can express the complete or partial polypeptide of the coded SARS coronavirus S protein in vivo. The described gene vaccine can be used for immunizing host including human body and rodent, for example mouse to make it produce specific protective body fluid immune and cell immune to resist the infection of SARS coronavirus. Said invention is good in stability, convenient in production and low in cost.

The present invention discloses the specific monocloneal antibody of SARS-CoV nuclear capsid protein, hybrid tumor producing the antibody, reagent containing the monocloneal antibody and reagent kit therewith. The monocloneal antibody is secreted and produced with the cell line including hybrid tumor 1E8A11 of preservation number of CCTCC-C200401, hybrid tumor 1E8A17 of preservation number of CCTCC-C200402, hybrid tumor 10E4A4 of preservation number of CCTCC-C200403, and hybrid tumor 14A3A3A19 of preservation number of CCTCC-C200404. The reagent kit established with the monocloneal antibody may be used in early diagnosis of SARS-CoV infection and has the features of simplicity, convenience, fastness, high sensitivity, powerful specificity, etc.

Nucleic acid molecules, polypeptides, immunogenic compositions, vaccines, and methods of making and using the nucleotides and encoded polypeptides associated with the Spike protein of SARS Corona Virus (SARS CoV) are disclosed.

The present invention relates to a surface expression vector of SARS coronavirus antigen containing a gene encoding an antigen of SARS inducing coronavirus and any one or two or more of genes pgsB, pgsC and pgsA encoding poly-gamma-glutamic acid synthase complex, a microorganism transformed by the surface expression vector, and a SARS vaccine comprising the microorganism. According to the present invention, it is possible to economically produce a vaccine for prevention and treatment of SARS using a recombinant strain expressing an SARS coronavirus antigen on their surface.